Unlocking a New Era in Lung Cancer Treatment With Durvalumab and Ceralasertib

Phase II trial finds durvalumab plus ceralasertib boosted immune response and improved outcomes in patients with lung cancer. A specific combination of targeted therapy and…

Read More